Abstract: A metabolomic signature of acute mesenteric ischemia (AMI) and the determination thereof in a method for identifying a subject suffering or being at risk of suffering from AMI. Also, a kit that includes elements for determining the metabolomic signature of AMI and implementing the method for identifying a subject suffering or being at risk of suffering from AMI.

Abstract: The invention relates to quality control devices and methods for magnetic resonance imaging (MRI) systems, more particularly for medical imaging applications. An example is stereotactic surgery where MRI images are combined with X-ray images to accurately locate a target in a subject. A test device (1), and an associated method using said test object, are used to easily detect a faulty calibration or a malfunction of an MRI device. The test device includes: a hermetically sealable hollow body (20) having a substantially cylindrical shape, a support frame (22) configured to be removably inserted in the hollow body and defining a target region (V22) having a substantially cylindrical shape; and a plurality of target objects (24) made of a material visible on X-ray images and MRI images said target objects being arranged in the target region and being attached to the support frame.

Abstract: The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.

Abstract: The invention features compositions and methods for introducing mutations into the hepatitis B virus (HBV) genome.

Abstract: The invention provides a clonal cell line derived from a liver cancer cell line, preferably derived from a Huh7 hepatocarcinoma cell line, engineered to produce and secrete viral particles containing pregenomic RNA of the hepatitis B virus (HBV), predominantly over DNA of HBV, to calibrate quantitative HBV RNA assays.

Abstract: The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas genus bacteria in a biological sample obtained from said subject.

Abstract: HSP110 inhibitors bind directly to the nucleotide binding domain of HSP110 and then block the phosphorylation of STAT3, cancer cell growth or MyD88 stability. Aspects involve a compound of formula (I) for use in the treatment of a HSP110-associated cancer, for example colorectal cancer and lymphoma. An examplary compound was tested on a syngeneic model for which mouse colon cancer CT-26 cells were injected into Balb/c mice and on a NOD/SCID model in which mice were implanted with human colorectal cancer HCT116 cells. In those animals bearing a tumor, the compound induced tumor regression that was associated with the inhibition of other HSP110 reported tumorigenic functions (resistance to apoptosis, induction of pro-tumor macrophages). Further, the compound was tested on large B cell lymphoma cell lines (DLBCL) and it was able to alter the interaction between HSP110 and MyD88, which induces a degradation of the oncogene MyD88.

Abstract: The invention relates to the field of cell therapy and to an in vitro method for generating T-cell progenitors, comprising the step of exposing CD34+ cells in a medium containing a Notch ligand, a soluble domain of the Delta-like ligand 4, joined to an Fc region of a protein IgG, in the presence of a fragment of fibronectin comprising the motifs RGDS and CS-1 and a heparin-binding domain.

Abstract: A method for determining a flow rate and/or a concentration of particles of a fluid flowing in a chamber, which includes the steps of: producing an ultrasound beam of a given frequency with a first transducer such that all fluid components traveling through an intersection region between the ultrasound beam and the chamber are insonated by the first transducer; receiving Doppler-shifted ultrasound signals generated by the fluid components in the insonated region of the chamber with a second transducer; acquiring the ultrasound signals received by the second transducer during an acquisition time; obtaining a Doppler Power Spectrum of the acquired ultrasound signals; and determining the flow rate and/or the concentration of particles of the fluid by adjustment between, on the one hand, the obtained Doppler Power Spectrum and, on the other hand, a model of the Doppler Power Spectrum.

Abstract: The present invention relates to the activation of FGF10 signaling pathway for use in the treatment of a heart disease.

Abstract: The invention relates to methods and pharmaceutical compositions for the treatment and diagnosis of cancer. The invention also relates to methods and pharmaceutical compositions for the treatment of inflammatory diseases and autoimmune diseases. The inventors investigate the role and specific contribution of extracellular vesicles (EVs) in cancer environment. The inventors demonstrate that CSF1-associated EVs induce macrophage signature associated with T cell infiltration and extended patient survival. The inventors demonstrate that via specific extracellular vesicles, these tumors promote pro-inflammatory macrophages correlated with better clinical outcome and a better prognosis in TNBC patients. In the present invention, the inventors provide in vitro evidences towards a direct role of CSF1-associated EVs as tools, alone or with other immuno-therapies, to promote anti-tumor immune responses.

Abstract: Provided herein is a method for detecting a tumour that can be applied to cell-free samples, to cell-free detect circulating tumour DNA. The method utilizes detection of adjacent methylation signals within a single sequencing read as the basic positive tumour signal, thereby decreasing false positives. The method comprises extracting DNA from a cell-free sample obtained from a subject, bisulphite converting the DNA, amplifying regions methylated in cancer (CpG islands, CpG shores, and/or CpG shelves), generating sequencing reads, and detecting tumour signals. To increase sensitivity, biased primers designed based on bisulphite converted methylated sequences can be used. Target methylated regions can be selected from a pre-validated set according to the specific aim of the test. Absolute number, proportion, and/or distribution of tumour signals may be used for tumour detection or classification.

Abstract: Provided herein is a method for detecting a tumour that can be applied to cell-free samples, to cell-free detect circulating tumour DNA. The method utilizes detection of adjacent methylation signals within a single sequencing read as the basic positive tumour signal, thereby decreasing false positives. The method comprises extracting DNA from a cell-free sample obtained from a subject, bisulphite converting the DNA, amplifying regions methylated in cancer (CpG islands, CpG shores, and/or CpG shelves), generating sequencing reads, and detecting tumour signals. To increase sensitivity, biased primers designed based on bisulphite converted methylated sequences can be used. Target methylated regions can be selected from a pre-validated set according to the specific aim of the test. Absolute number, proportion, and/or distribution of tumour signals may be used for tumour detection or classification.

Abstract: A portable imaging system for visualizing a biological target structure by a tracking element introduced therein, including: a control unit with a memory for storing at least one ultrasound image of the target structure, a probe to be removably fixed to a biological fixing structure surrounding at least partially the target structure, the probe being connected to the control unit, and a positioning assistance module of the probe. The probe is capable of detecting the tracking element by means of ultrasound, the control unit being able to locate it, in real time, inside the target structure, so as to characterize it geometrically and create the ultrasound image. The control unit can also display it on a display device. The ultrasound image allows rapid diagnosis to be made independently of any location and environment.

Abstract: An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.

Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

Abstract: A transgenic non-human animal model for Neurofibromatosis type 1, wherein the Nf1 gene is specifically inactivated in BC cells and derivatives thereof. Also, an in vitro method of producing cutaneous and plexiform Neurofibromas (NFBs) and/or for studying the development and composition of plexiform NFBs, including culturing in vitro Prss56-expressing cells and-derivatives thereof obtained from the transgenic non-human animal model. Further, a method for screening a candidate compound for use as a drug to treat Neurofibromatosis type 1, cutaneous NFBs and/or plexiform NFBs including contacting the candidate compound Prss56-expressing cells and-derivatives thereof obtained from the transgenic non-human animal model or administering the candidate compound to the transgenic non-human animal model.

Abstract: A method for obtaining a population of T cells from pluripotent stem cells, which includes a first step of obtaining hematopoietic stem cells and a second step of obtaining T cells. Also, the cell populations thus obtained according to this method and these cell populations for use as a medicament.

Abstract: The present disclosure relates to bispecific antibodies targeting EGFR and HER2, and methods for the production of these antibodies. The bispecific antibodies consist of one complete antibody on which two VH-VL chains are attached via a linker to each NH terminal region of both VH chains of the antibody. The bispecific antibodies constructed use the amino acid sequences of the heavy chain (VH) and the light chain (VL) variable regions of two monoclonal antibodies targeting EGFR and HER2, namely cetuximab and trastuzumab, respectively.

Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.